Tofidence (tocilizumab-bavi) vs Ilaris (canakinumab)

Tofacitinib, often referred to by its brand name Xeljanz, is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions by modulating the immune system, whereas tocilizumab-bavi, a biosimilar to Actemra (tocilizumab), is an interleukin-6 (IL-6) receptor antagonist used for similar purposes, such as rheumatoid arthritis and cytokine release syndrome. Canakinumab, marketed as Ilaris, is an interleukin-1 beta (IL-1β) blocker that primarily targets autoinflammatory syndromes like Cryopyrin-Associated Periodic Syndromes (CAPS) and systemic juvenile idiopathic arthritis. When deciding between these medications, it is crucial to consider the specific condition being treated, as each drug targets different pathways in the immune system, and to consult with a healthcare provider to assess which medication aligns best with the individual's medical history and treatment goals.

Difference between Tofidence and Ilaris

Metric	Tofidence (tocilizumab-bavi)	Ilaris (canakinumab)
Generic name	tocilizumab-bavi	canakinumab
Indications	Rheumatoid arthritis, giant cell arteritis, cytokine release syndrome	Cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease, familial Mediterranean fever
Mechanism of action	Interleukin-6 (IL-6) receptor inhibitor	Interleukin-1β (IL-1β) inhibitor
Brand names	Tofidence, Actemra	Ilaris
Administrative route	IV infusion, subcutaneous injection	Subcutaneous injection
Side effects	Upper respiratory tract infections, headache, hypertension, injection site reactions	Infections, neutropenia, nausea, vertigo, injection site reactions
Contraindications	Active, serious infections; known hypersensitivity to tocilizumab or any component of the formulation	Active, serious infections; known hypersensitivity to canakinumab or any component of the formulation
Drug class	Monoclonal antibody	Monoclonal antibody
Manufacturer	Genentech, Inc.	Novartis Pharmaceuticals Corporation

Efficacy

Efficacy of Tocilizumab-bavi (Tofidence) in Rheumatoid Arthritis

Tocilizumab-bavi, known by the brand name Tofidence, is a biosimilar to the original tocilizumab product. It is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which plays a key role in the inflammatory process of rheumatoid arthritis (RA). Clinical studies have demonstrated that Tofidence can significantly reduce the signs and symptoms of RA, including joint pain, swelling, and stiffness. It is approved for use in adult patients with moderate to severe active RA who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Tofidence has been shown to improve physical function and slow the progression of joint damage in patients with RA.

The efficacy of Tofidence in RA has been evaluated in several clinical trials. These studies have consistently shown that patients treated with Tofidence, in combination with methotrexate or as monotherapy, experience improved clinical outcomes compared to those receiving placebo or other DMARDs alone. The American College of Rheumatology (ACR) response criteria, which measure improvement in tender and swollen joint counts as well as other patient and physician-reported outcomes, have been used to assess the effectiveness of Tofidence in these trials. A significant proportion of patients treated with Tofidence achieved ACR20, ACR50, and ACR70 responses, indicating 20%, 50%, and 70% improvements respectively.

Efficacy of Canakinumab (Ilaris) in Rheumatoid Arthritis

Canakinumab, sold under the brand name Ilaris, is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), a cytokine that contributes to the inflammation and joint destruction in RA. While Ilaris is primarily known for its use in rare auto-inflammatory syndromes, it has also been investigated for its potential in treating RA. The efficacy of Ilaris in RA has been explored in clinical trials, and while it has shown some potential in reducing the signs and symptoms of the disease, it is not currently approved for the treatment of RA by regulatory agencies such as the U.S. Food and Drug Administration (FDA).

The clinical trials that have assessed the efficacy of Ilaris in RA patients have measured outcomes using the ACR response criteria as well as the Disease Activity Score 28 (DAS28), which is a measure of disease activity that includes the number of tender and swollen joints, a patient's assessment of their own disease activity, and a measure of inflammation. In these studies, Ilaris has demonstrated a reduction in disease activity and improvement in some patient-reported outcomes. However, the results have not been consistent across all studies, and further research is needed to fully understand the role of Ilaris in the treatment of RA.

Regulatory Agency Approvals

Tofidence

Food and Drug Administration (FDA), USA

Ilaris

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tofidence or Ilaris today

If Tofidence or Ilaris are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tofidence

Buy Ilaris

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: